PURPOSE OF REVIEW: To summarize the pathophysiology of, risk factors for, and outcomes of early Pseudomonas aeruginosa (Pa) infection in CF; to review the results of trials of early intervention and to describe treatment options for early Pa infection. RECENT FINDINGS: Chronic lower airway Pa infection is associated with significant morbidity and mortality among CF patients. However, first acquisition of Pa does not appear to cause an immediate and rapid decline in lung function. Early Pa isolates are generally non-mucoid, antibiotic-sensitive, and present at low density, suggesting a possible "window of opportunity" for early intervention. SUMMARY: Anti-pseudomonal therapy for early infection results in transient Pa eradication, but re-infection with Pa appears inevitable despite early aggressive treatment. There are no controlled trials demonstrating clinical benefit in young children. There is a critical need for further investigation of the clinical outcomes associated with early intervention, the long-term safety profile, and the optimal drug regimen.
PURPOSE OF REVIEW: To summarize the pathophysiology of, risk factors for, and outcomes of early Pseudomonasaeruginosa (Pa) infection in CF; to review the results of trials of early intervention and to describe treatment options for early Pa infection. RECENT FINDINGS: Chronic lower airway Pa infection is associated with significant morbidity and mortality among CFpatients. However, first acquisition of Pa does not appear to cause an immediate and rapid decline in lung function. Early Pa isolates are generally non-mucoid, antibiotic-sensitive, and present at low density, suggesting a possible "window of opportunity" for early intervention. SUMMARY: Anti-pseudomonal therapy for early infection results in transient Pa eradication, but re-infection with Pa appears inevitable despite early aggressive treatment. There are no controlled trials demonstrating clinical benefit in young children. There is a critical need for further investigation of the clinical outcomes associated with early intervention, the long-term safety profile, and the optimal drug regimen.
Authors: Deanna M Green; J Michael Collaco; Kathryn E McDougal; Kathleen M Naughton; Scott M Blackman; Garry R Cutting Journal: J Pediatr Date: 2012-02-23 Impact factor: 4.406
Authors: Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel Journal: J Cyst Fibros Date: 2016-10-27 Impact factor: 5.482
Authors: Camilla Margaroli; Luke W Garratt; Hamed Horati; A Susanne Dittrich; Timothy Rosenow; Samuel T Montgomery; Dario L Frey; Milton R Brown; Carsten Schultz; Lokesh Guglani; Anthony Kicic; Limin Peng; Bob J Scholte; Marcus A Mall; Hettie M Janssens; Stephen M Stick; Rabindra Tirouvanziam Journal: Am J Respir Crit Care Med Date: 2019-04-01 Impact factor: 21.405
Authors: Xuan Qin; Danielle M Zerr; Michael A McNutt; Jessica E Berry; Jane L Burns; Raj P Kapur Journal: Antimicrob Agents Chemother Date: 2012-09-10 Impact factor: 5.191
Authors: C E Wainwright; M W France; P O'Rourke; S Anuj; T J Kidd; M D Nissen; T P Sloots; C Coulter; Z Ristovski; M Hargreaves; B R Rose; C Harbour; S C Bell; K P Fennelly Journal: Thorax Date: 2009-07-01 Impact factor: 9.139